[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumocystis-jiroveci-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumocystis-jiroveci-pneumonia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100618235","phase-4-how-long-should-we-give-steroids-for-patients-with-severe-pcp-100618235",false,"NCT07328984","How Long Should we Give Steroids for Patients With Severe PCP","How Long Should we Give Steroids for Patients With Severe PCP (HOW LONG)","HOW LONG","Inclusion Criteria:\n\n* Age ≥18 years\n* Proven or probable Pneumocystis jirovecii pneumonia\n* Severe PCP requiring supplemental oxygen (e.g., ≥4 L\u002Fmin or ≥35% FiO₂ to maintain SpO₂ ≥94%)\n* Planned or receiving adjunctive systemic corticosteroid therapy for severe PCP\n* Clinical recovery by day 10 of steroid therapy: breathing room air for ≥6 hours\n* Able to provide informed consent (or per local requirements)\n\nExclusion Criteria:\n\n* Persistent hypoxemia or ongoing oxygen requirement at day 10\n* Clinical deterioration prior to randomization\n* Treating clinician determines steroids must be continued or stopped immediately for medical reasons\n* Anticipated death within 48 hours\n* Inability or unwillingness to complete follow-up through day 180","ALL","18 Years",{"count":20,"type":21},416,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.",[27,28,29,30,31,32,33],"Pneumocystis Pneumonia","Pneumocystis","Pneumocystis Jirovecii Infection","Pneumocystis Jiroveci Pneumonia","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystosis Associated With AIDS","Pneumocystosis; Pneumonia (Etiology)",[35,36,37,38,39,40,41,42],"PCP","Systemic Corticosteroids","De-escalation of Therapy","Randomized Control Trial","Immunocompromised host","HIV","Non-HIV","Pneumocystis jirovecii pneumonia","NOT_YET_RECRUITING","2025-12-27",{"date":46,"type":47},"2026-01-09","ACTUAL",{"date":49,"type":21},"2026-01-30",{"date":51,"type":21},"2029-06",{"name":53,"class":54},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100604676","phase-3-corticosteroids-for-pjp-in-non-hiv-immunocompromised-adults-100604676","NCT07152613","Corticosteroids for PJP in Non-HIV Immunocompromised Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Pneumocystis Jirovecii Pneumonia (PJP) in Non-HIV Immunocompromised Patients","CAPSTONE-PJP","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nAdmission to the Intensive Care Unit (ICU).\n\nMeeting the diagnostic criteria for community-acquired pneumonia (CAP).\n\nMeeting at least one of the major diagnostic criteria for severe pneumonia:\n\n(i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\nOr simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\nConfirmed PJ etiology: at least one positive nucleic acid test (PCR) or next-generation sequencing (NGS) result for Pneumocystis jirovecii in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n\nSevere community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnant or breastfeeding women.\n* HIV infection.\n* No targeted PJP therapy administered or therapy not according to standard protocol.\n* Diagnosis of PJP \\>7 days prior to MICU admission.\n* Use of corticosteroids for PJP prior to MICU admission.\n* Requirement for high-dose baseline corticosteroid therapy for other conditions (prednisone ≥ 0.5 mg\u002Fkg\u002Fday or equivalent).\n* Any contraindication to corticosteroid use as judged by the investigator (e.g., severe concurrent infectious disease, severe gastrointestinal bleeding).\n* Discharge or death within 48 hours after intervention.\n* Participation in other clinical studies or refusal to participate in this study.",{"count":65,"type":21},240,[67],"PHASE3","Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%. Reducing mortality from PJP is crucial for improving outcomes in critically ill non-HIV immunocompromised patients and alleviating the burden on families and society. To address this medical challenge, our institution is conducting a study aimed at lowering PJP-related mortality. Specifically, we are performing an adaptive, randomized, open-label controlled trial in patients with severe PJP. The primary objective of this study is to scientifically evaluate the efficacy and safety of adjunctive corticosteroids at different dosages, in addition to early standard supportive care, for reducing mortality in severe PJP",[30],[71,72,73,74],"community-acquired pneumonia","Pneumocystis jiroveci","non-HIV","corticosteroids","2025-09-02",{"date":77,"type":47},"2025-09-09",{"date":79,"type":21},"2025-09-08",{"date":81,"type":21},"2027-12-31",{"name":83,"class":54},"Qingyuan Zhan"]